Results 151 to 160 of about 5,452,327 (324)

Fundamental Studies on the Transport of Substances Across Biological Membranes-III

, 1967
Masa SHIRATORI, Haruo Mizuno, Masanori OKAMOTO, Yatuhiro TABATA   +3 more
openalex   +2 more sources

Transplasma membrane electron transport: enzymes involved and biological function [PDF]

, 2003
Jennifer Ly, Alfons Lawen
openalex   +1 more source

MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NFκB axis

Molecular Oncology, EarlyView.
mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).
Jesús García‐Castillo, Carlos M. Martínez‐Cáceres, Manuel Bernabé‐García, Vicente Munitiz, David Ruiz de Angulo, Pascual Parrilla, Ángeles Ortiz, Luisa F. Martínez de Haro, María L. Cayuela   +8 more
wiley   +1 more source

Organic Mixed Ionic–Electronic Conductors for Bioelectronic Sensors: Materials and Operation Mechanisms

Advanced Science
The field of organic mixed ionic‐electronic conductors (OMIECs) has gained significant attention due to their ability to transport both electrons and ions, making them promising candidates for various applications.
Hyunwook Kim, Yousang Won, Hyun Woo Song, Yejin Kwon, Minsang Jun, Joon Hak Oh   +5 more
doaj   +1 more source

Biological transport of curium-243 in dairy animals. [Comparison to /sup 241/Am kinetics in lactating cows and goats]

, 1979
W.W. Sutton, R. G. Patzer, P. B. Hahn, G.D. Potter   +3 more
openalex   +2 more sources

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

A covalent organic framework membrane with highly selective and permeable artificial sodium channels via ion recognition

Nature Communications
Biological sodium channels efficiently discriminate between same–charge ions with similar hydration shells. However, achieving precise ion selectivity and high throughput in artificial ion channel fabrication remains challenging.
Jing Wang, Junwei Zhang, Pengrui Jin, He Wen, Ziwen Dai, Hao Tan, Shushan Yuan, Jiakuan Yang, Menachem Elimelech   +8 more
doaj   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

Studies of Proton Translocations in Biological Systems: Simulating Proton Transport in Carbonic Anhydrase by EVB-Based Models [PDF]

, 2004
Sonja Braun‐Sand, Marek S̆trajbl, Arieh Warshel   +2 more
openalex   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source